Evaluating the UNICA system for the treatment of severe tricuspid regurgitation.

Despite significant advances in transcatheter tricuspid valve repair and replacement (TTVR), a substantial proportion of patients with severe tricuspid regurgitation (TR) remain ineligible for currently available therapies due to anatomical constraints, advanced disease, or prohibitive procedural risk. Heterotopic valve implantation strategies, in which prosthetic valves are positioned outside the native tricuspid annulus, have emerged as alternative approaches for this challenging population. The UNICA system represents a novel single-stent, double valve heterotopic platform designed for patients with symptomatic severe TR who are unsuitable for surgical or transcatheter annular interventions. Early clinical experience suggests high technical success, short procedural times, favorable short-term safety, and meaningful improvements in functional status and quality of life. Mechanistically, the system offers potential advantages over existing TTVR devices by bypassing complex annular anatomy and simplifying procedural execution. Nevertheless, further prospective data is required to define long-term durability, optimal patient selection, and comparative effectiveness.